MedTrace Logo

Combination Chemotherapy in Treating Men With Germ Cell Cancer

NCT00003643 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 498

Last updated 2012-03-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy may be more effective for germ cell cancer.

PURPOSE: This randomized phase II/III trial is studying two different regimens of combination chemotherapy and comparing how well they work in treating men with germ cell cancer.

Conditions

  • Extragonadal Germ Cell Tumor
  • Teratoma
  • Testicular Germ Cell Tumor

Interventions

BIOLOGICAL

bleomycin sulfate

BIOLOGICAL

filgrastim

DRUG

cisplatin

DRUG

etoposide

DRUG

paclitaxel

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Ronald De Wit, MD, PhD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31

Countries

  • Austria
  • Belgium
  • Denmark
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003643 on ClinicalTrials.gov